A landmark clinical trial was announced in November when a $9 million grant was provided for the first human study using stem cells to treat a spinal disorder that occurs in babies in the womb.

Voters approved a proposition to provide $5.5 billion for stem cell research by the California Institute of Regenerative Medicine, according to a Nov. 13 press release.

The first human clinical trial using stem cells to treat spina bifida has been made possible thanks to a $9 million grant provided Nov. 12 by the California Institute for Regenerative Medicine.

CelluBridge, a spinal cord scaffold implant, has received the FDA's breakthrough device designation.

A man who had shoulder pain turned to stem cells to aid his recovery from rotator cuff surgery, according to a Nov. 11 report from ABC12.

Cerapedics' i-Factor+ Matrix is now available for surgical implantation in Canada.

Cells in cellular bone matrix products do not improve fusion or bone formation, according to results of a preclinical SeaSpine study published in The Journal of Bone and Joint Surgery.

The American Academy of Orthopaedic Surgeons on Oct. 15 introduced the AAOS Biologics Dashboard to help physicians keep up to date with the approval status of biologic innovations.

A Wisconsin stem cell clinic has been cautioned by the FDA for marketing intrathecal and intravenous injections of human stem cell and tissue-based products for a variety of neurologic conditions, according to the Regulatory Affairs Professionals Society.

Orthobiologic company Biologica Technologies on Oct. 6 launched OsseoGen, a cellular bone matrix designed for bone regeneration.

Regenerative medicine company Aziyo Biologics on Sept. 28 appointed Matthew Ferguson as CFO.

Regenerative medicine company Histogen has received a $2 million grant to help fund a clinical trial for knee cartilage regeneration.

Richmond, Va.-based VCU Health spine surgeon Rick Placide, MD, implanted the first Signafuse strips in a patient during a posterolateral lumbar fusion, according to a Sept. 2 news release.

A number of emerging biologic technologies are currently being evaluated and launched in the spine field. Here are six key developments in the past month:

Orthobiologics company Kuros Biosciences has treated the first patient in its clinical trial evaluating Fibrin-PTH for transforaminal lumbar interbody fusion in patients with degenerative disc disease.

Orthobiologics company Royal Biologics acquired the Fibrinet system from Vertical Spine Sept. 1.

Biopharmaceutical company DiscGenics has raised $50 million in a Series C funding round, according to an Aug. 25 news release.

The Steadman Philippon Research Institute in Vail, Colo., has received a grant from the National Institutes of Health to study the use of bone marrow stem cells to delay osteoarthritis in the knee.

The FDA has cleared Genentech's Evrysdi drug for spinal muscular atrophy in adults and children 2 months of age and older, according to an Aug. 10 announcement.

More than 6,000 members have joined the Biologic Association within the first six months of its website launch.